c-Fms-IN-9 |
| Catalog No.GC35666 |
c-Fms-IN-9 est un inhibiteur de c-FMS extrait du brevet WO2014145023A1, exemple composé 7. c-Fms-IN-9 inhibe la c-FMS kinase non phosphorylée (uFMS) et uKIT avec des IC50 <0,01 μM et 0,1-1 μM, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1628574-50-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively[1]. c-FMS[1]
c-Fms-IN-9 inhibits M-NFS-60, THP-1 and osteoclast cells proliferation with IC50s of 0.01-0.1 μM[1].
[1]. Gary E. L. BRANDT, et al. 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145023A1.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *